Unravelling the effect of blood group on FVIII:C levels and response to DDAVP in 20 males with a single genotype (Twillingate Variant) causing Haemophilia A

Haemophilia. 2024 Jan;30(1):116-122. doi: 10.1111/hae.14896. Epub 2023 Nov 30.

Abstract

Introduction: The genetic variant responsible for haemophilia A (HA) significantly impacts endogenous coagulant factor VIII (FVIII:C) level, thus impacting DDAVP responsiveness. Blood group (BG) also impacts FVIII:C levels, but this is difficult to evaluate in a genetically heterogeneous population. Canada has a large cohort of mild-moderate HA due to a single point variant: c.6104T>C, p.Val2035Ala-the Twillingate variant.

Aim: To evaluate the impact of BG on endogenous FVIII:C levels and DDAVP responsiveness in a single genotype of mild-moderate HA.

Methods: This was a retrospective, single-centre study. BG and FVIII:C levels were obtained for males with the Twillingate variant. One-hour absolute and fold increases in FVIII:C post-DDAVP were calculated. T-tests and Mann-Whitney U tests were used to compare FVIII:C levels and DDAVP challenge variables between individuals according to BGs (O vs. non-O).

Results: Twenty males were included. There were significant differences between BGs (O vs. non-O) in their lowest FVIII:C level at age <12 years (medians: 0.05 vs. 0.08 IU/mL; P = .05). Fifteen subjects underwent DDAVP challenges. Mean 1-h FVIII:C were 0.29 (O BG) versus 0.41 IU/mL (non-O BG); P = .04. There were no significant differences between BGs (O vs. non-O) in mean absolute FVIII:C increase (0.20 vs. 0.27 IU/mL; P = .10) and FVIII:C fold increase (3.3-fold vs. 3.8-fold; P = .51).

Conclusion: In HA subjects with an identical genotype, BG significantly impacts baseline FVIII:C levels and FVIII:C levels post-DDAVP, but does not impact absolute and fold increases in FVIII:C with DDAVP.

Keywords: blood group antigens; deamino arginine vasopressin (DDAVP); factor VIII; haemophilia A; von Willebrand factor.

MeSH terms

  • Blood Group Antigens*
  • Child
  • Deamino Arginine Vasopressin / therapeutic use
  • Factor VIII / genetics
  • Genotype
  • Hemophilia A* / drug therapy
  • Hemophilia A* / genetics
  • Humans
  • Male
  • Retrospective Studies
  • von Willebrand Diseases*
  • von Willebrand Factor / genetics

Substances

  • Deamino Arginine Vasopressin
  • Blood Group Antigens
  • Factor VIII
  • von Willebrand Factor